Physician profile
Sarah E Schram
NPI 1720268188
$2,676.38
in general payments reported to CMS, 2019-2025
21 companies · $421 in 2025
The $421 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $314 · 2020: $107 · 2021: $192 · 2022: $366 · 2023: $708 · 2024: $568 · 2025: $421.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,602 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,601.56 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $485.56 | 2019-2025 | Rinvoq |
| Allergan, INC. | $291.23 | 2019-2022 | |
| Genzyme Corporation | $235.16 | 2020-2023 | |
| Lilly USA, LLC | $204.84 | 2019-2025 | Taltz, Ebglyss |
| Janssen Biotech, INC. | $203.50 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Leo Pharma INC. | $187.99 | 2019-2025 | Adbry, Anzupgo |
| Smith+Nephew, INC. | $154.02 | 2023 | Grafix Pl |
| Novartis Pharmaceuticals Corporation | $145.53 | 2019-2025 | |
| Ucb, INC. | $121.42 | 2019-2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $114.62 | 2019-2023 | Libtayo |
| Sun Pharmaceutical Industries INC. | $112.32 | 2019-2024 | Ilumya |
| Sanofi-Aventis U.S. LLC | $94.99 | 2025 | |
| Galderma Laboratories, L.P. | $59.64 | 2022-2025 | Nemluvio |
| Amgen INC. | $58.63 | 2024-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $50.63 | 2023 | Sotyktu |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $41.16 | 2019-2025 | Ameluz |
| Incyte Corporation | $38.50 | 2024 | Opzelura |
| Arcutis Biotherapeutics, INC. | $21.13 | 2024 | Zoryve |
| Organogenesis INC. | $21.08 | 2023 | Puraply |
| Dusa Pharmaceuticals, INC. | $19.65 | 2019 | |
| Almirall LLC | $14.78 | 2025 | Klisyri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Schram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.